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Abstract 
DNA replication precisely duplicates the genome to ensure stable inheritance of genetic 
information.  Impaired licensing of origins of replication during the G1 phase of the cell cycle 
has been implicated in Meier-Gorlin syndrome (MGS), a disorder defined by the triad of 
short stature, microtia and a/hypoplastic patellae. Biallelic partial loss-of-function mutations 
in multiple components of the pre-replication complex (preRC; ORC1, ORC4, ORC6, CDT1 
or CDC6) as well as de novo stabilizing mutations in the licencing inhibitor, GMNN, cause 
MGS. Here we report the identification of mutations in CDC45 in 15 affected individuals 
from 12 families with MGS and/or craniosynostosis.  CDC45 encodes a component of both 
the pre-initiation (preIC) and CMG helicase complexes, required respectively for initiation of 
DNA replication origin firing and ongoing DNA synthesis during S-phase itself, hence is 
functionally distinct from previously identified MGS-associated genes. The phenotypes of 
affected individuals range from syndromic coronal craniosynostosis to severe growth 
restriction, fulfilling diagnostic criteria for Meier-Gorlin syndrome. All mutations identified 
were biallelic and included synonymous mutations altering splicing of physiological CDC45 
transcripts, as well as amino acid substitutions expected to result in partial loss of function. 
Functionally, mutations reduce levels of full-length transcripts and protein in subject cells, 
consistent with partial loss of CDC45 function and a predicted limited rate of DNA 
replication and cell proliferation. Our findings therefore implicate the preIC as an additional 
protein complex involved in the etiology of MGS, and connect the core cellular machinery of 
genome replication with growth, chondrogenesis and cranial suture homeostasis.  
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Introduction 
Replication of DNA during eukaryotic cell division is an essential process, which requires a 
complex apparatus of conserved proteins operating under tight temporal and regulatory 
control. Although the duplication process itself occurs during the S (synthesis) phase of the 
cell cycle, the initial components assemble on DNA much earlier, during the late mitotic 
stages and in G1 phase.  
In the first stage, the pre-replication complex (preRC) is formed by the 6-subunit origin 
recognition complex (ORC) binding to replication origins distributed throughout the genome 
(Figure 1).1 ORC recruits CDT1 and CDC6, which leads to the binding of the inactive 
MCM2-7 helicase as a double hexamer at replication origins.2 At the G1/S transition the pre-
initiation complex (preIC) proteins assemble in a two-step DDK- and CDK-dependent 
manner3 and through interaction with the MCM helicase enable binding by the CDC45 and 
GINS1-4 proteins. This creates the activated CMG helicase, an eleven-subunit complex that 
possesses essential DNA unwinding activity, allowing polymerases access to DNA and 
enabling replication to commence.4, 5, 6, 7, 8 CDC45 has single-stranded DNA binding activity, 
facilitating DNA strand displacement at the replication fork.9 Hence CDC45 plays a central 
role both in initiation of DNA replication origin firing (preIC) and ongoing DNA synthesis 
(CMG helicase), and genetic studies demonstrate that it is essential in both yeast and mice.10, 
11, 12, 13, 14 Both in vitro and in vivo data indicate that CDC45 is loaded onto chromatin 
specifically in the S phase of the cell cycle, after the assembly of the preRC complexes.11, 14, 
15, 16, 17 
Several Mendelian syndromes have been associated with mutations in components of 
the DNA replication machinery. Meier-Gorlin syndrome (MGS) (MIM 224690) is 
characterised by short stature, microtia (small ears) and aplasia or hypoplasia of the 
patellae.18 Biallelic mutations in multiple components of the preRC (ORC1 [MIM 601902], 
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ORC4 [MIM 603056], ORC6 [MIM 607213], CDT1 [MIM 605525] and CDC6 [MIM 
602627]) were identified in individuals with MGS, 19, 20, 21 and among them, mutations in 
these genes account for approximately 70% of cases.22 Recently, de novo mutations in three 
individuals were reported in the CDT1 inhibitor, GMNN (MIM 602842), resulting in the 
omission of a degron domain that stabilises GMNN levels and is consequently predicted to 
impair licensing in subject cells.23, 24   
Here, we provide genetic and functional evidence that mutations in CDC45 (MIM 
603465) cause human disease. We describe 15 individuals with biallelic partial loss of 
function mutations in CDC45 and demonstrate a phenotype that extends from syndromic 
craniosynostosis to classical MGS. 
 
Subjects and Methods 
 
Clinical studies 
The clinical studies were approved by Oxfordshire Research Ethics Committee B (reference 
C02.143), London Riverside Research Ethics Committee (reference 09/H0706/20), Scottish 
Multicentre Research Ethics Committee (04:MRE00/19) and the Medisch Ethische 
Toetsingscommissie of the Leiden University Medical Center (LUMC) (P14-029). Subjects 
were enrolled into the craniosynostosis cohort based on referral from a craniofacial unit or 
clinical genetics department, with craniosynostosis proven on either plain radiographs or 
computed tomography (CT) of the skull. Individuals in the MGS cohort were clinically 
diagnosed by the referring clinician; in those from whom clinical data were available, all 
demonstrated hypoplastic or absent kneecaps, small or simple ears, and facies typical of MGS 
(small mouth and full lips). All participants gave informed consent, and separate permission 
was obtained for publication of clinical photographs. 
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Whole genome and exome sequencing 
Subjects P1 (Family 1, II-3 in Figure 2A) and P2 (Family 2, II-1 in Figure 2A), from a 
craniosynostosis cohort, were subjected to whole genome sequencing and exome sequencing, 
respectively. Exome sequencing of subject P4 (Family 4, II-1 in Figure 2A) was undertaken 
by Oxford Gene Technology, as part of a study of subjects with primordial dwarfism 
(characterised by in utero growth retardation, and postnatal head circumference and height 
more than 4 standard deviations below the age- and gender-matched population mean). 
Exome sequencing of Family 12 was undertaken as part of a diagnostic approach to mutation 
identification. All details of sequencing library preparations and platforms, as well as 
software tools for mapping, alignment and variant calling and prioritization are presented in 
Table S1.  
 
Genomic analysis of CDC45 
To investigate further the significance of the CDC45 variants, primers were designed for 
amplification of genomic DNA (GenBank: NT_011520.13) and cDNA (GenBank: 
NM_003504.4; see Supplemental Data, Note on accession numbers for CDC45). We used 
dideoxy-sequencing to confirm the identity of CDC45 variants identified during whole 
genome and exome sequencing, and analyzed their segregation in parents and unaffected 
siblings. Primer sequences and experimental conditions used for PCR amplification and 
sequencing are provided in Table S2. To analyze a larger number of individuals for CDC45 
mutations, we used Fluidigm/Ion Torrent resequencing or dideoxy-sequencing, respectively, 
to screen CDC45 in DNA panels from subjects with craniosynostosis (467 samples) or MGS 
(34 samples), in whom mutations in known causative genes had not previously been 
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identified (Table S2). Multiplex ligation-dependent probe amplification (MLPA) was used to 
confirm the intragenic deletion in Family 12 (Table S2). 
 
Analysis of CDC45 splicing 
Total RNA was extracted from lymphoblastoid cell lines using Trizol reagent (Invitrogen) 
and the RNeasy kit (Qiagen) according to the manufacturer's instructions. DNA was removed 
by treatment with DNase I (Qiagen). cDNA was generated using random oligomer primers 
and superscript II (Thermo Fisher) or the RevertAid First Strand Synthesis kit (Fermentas). 
Primers used for RT-PCR and qRT-PCR are listed in Table S3. cDNA levels were quantified 
by qRT-PCR using Brilliant II SYBR green qPCR master mix with passive ROX reference 
dye (Agilent Technologies) on the ABI Prism HT7900 Sequence Detection System. The 
relative expression of target genes to a control was calculated using the comparative CT 
method (2-ΔΔCT) method.  
 
Cell lines, chemicals, plasmids and transfections 
Lymphoblastoid cell lines were cultured in RPMI-1640 supplemented with 15% fetal bovine 
serum (FBS) and 1% penicillin and streptomycin. Amniocytes were cultured in Amnio-MAX 
C-100 Complete Medium (Gibco). All reagents were purchased from Life Technologies 
unless otherwise stated.  
 
Antibodies and Western blotting 
Whole cell lysate was prepared using urea buffer (9 M urea, 50 mM Tris HCl, pH 7.3, 150 
mM β-mercaptoethanol). Primary antibodies used were mouse anti-human CDC45 (sc55569, 
Santa Cruz Biotech) at 1:1000 and mouse anti-human TUBULIN (B512, Sigma) at 1:10000. 
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Protein alignments and structure prediction 
Clustal Omega25 was used to generate multi-sequence alignments of orthologous CDC45 
proteins. Accession numbers are: Homo sapiens NP_003495.1, Pan troglodytes 
XP_009436063.1, Canis lupus XP_543547.3, Mus musculus NP_033992.2, Gallus gallus 
XP_415070.2, Danio rerio NP_998551.1, Drosophila melanogaster NP_569880.1, 
Anopheles gambiae XP_320573.1, Caenorhabditis elegans NP_497756.2, Saccharomyces 
cerevisiae NP_013204.1, Schizosaccharomyces pombe NP_594693.1. The structural model 
of human CDC45 was modelled on the 3.7Å cryo-electron microscopy structure of S. 
cerevisiae Cdc45.26 It was created using Modeller27 and is presented using Pymol 
(Schrodinger). 
 
Results 
Exome and Genome Sequencing and Targeted Resequencing Identify Biallelic Variants 
in CDC45 
As part of a large multi-disease study,28 clinical whole genome sequencing of a trio 
comprising a male individual (P1, Family 1:II-3 in Figure 2A) with syndromic unilateral 
coronal craniosynostosis and his unaffected parents, initially identified several candidate 
variants for further scrutiny. These were a single de novo missense mutation (FLRT1 [MIM: 
604806] c.137C>T, p.T46M [NM_013280.4]), two very rare (absent in dbSNP135, ESP or 
1000 Genomes) hemizygous nonsynonymous variants (OPHN1 [MIM 300127] c.1559C>T, 
p.Thr520Ile [NM_002547.2] and GEMIN8 [MIM 300962] c.500G>A, p.Arg167His 
[NM_017856.2]) and two very rare compound heterozygous genotypes: CDC45 c.[318C>T; 
c.677A>G], p.[Val106=; Asp226Gly], and MYO10 [MIM 601481] c.[1491G>A; 5459A>C], 
p.[Glu497=; His1820Pro] (NM_012334.2). FLRT1 was initially prioritized for further 
analysis, but resequencing this gene in a panel of 230 individuals with craniosynostosis 
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revealed no further mutations. During concurrent exome sequencing of female subject P2 
(Family 2:II-1 in Figure 2A) with syndromic bilateral coronal craniosynostosis, variant 
analysis under a recessive model of inheritance also identified two very rare predicted 
missense changes in CDC45 (c.226A>C, p.Asn76His and c.469C>T, p.Arg157Cys); 
dideoxy-sequencing of parental samples showed that the CDC45 variants were present in a 
compound heterozygous (biallelic) state. Given the identification of two individuals with 
unilateral or bilateral coronal or craniosynostosis, each of whom had two rare biallelic 
variants in CDC45 (Table 1), resequencing of CDC45 was undertaken in a further 467 
subjects with craniosynostosis. This revealed one further individual (P3, Family 3:II-1 in 
Figure 2A) with two rare CDC45 variants (Table 1), which analysis of parental samples 
showed were also biallelic. Consistent with a causal role in the disease state, three unaffected 
siblings of P1 and P2 inherited different combinations of CDC45 alleles (Figure 2A).  
In addition to craniosynostosis, clinical features variably present in individuals P1-P3 
included mild short stature, microcephaly and ear anomalies (Figure 2B, Table 2). In view of 
the previous association of replication-associated genes with growth restriction,19, 20, 21, 22 we 
interrogated exome sequencing data from a cohort of individuals with primordial dwarfism (n 
= 52) for variants in CDC45. One individual (P4, Family 4:II-1 in Figure 2A), diagnosed with 
MGS, was found to harbor two rare CDC45 variants (Table 1). 
Given the presentation of subject P4 with MGS, we then undertook dideoxy-sequencing 
of 34 further subjects with MGS, in whom causative mutations had not previously been found 
in preRC components. This identified seven further families (Family 5- Family 11) (Table 1), 
in which nine individuals have biallelic mutations in CDC45. All variants had either a very 
low allele frequency in control populations with no homozygotes, appropriate for a rare 
recessively inherited Mendelian disorder, or were absent from the ExAC dataset. The 
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autosomal recessive inheritance was confirmed by appropriate segregation in all parents 
where available (Figure 2A, Table 1). 
Concurrently, exome sequencing was undertaken in a nonconsanguineous Dutch family 
(Family 12) in which two consecutive fetuses displayed craniosynostosis and additional 
anomalies in utero. The recurrence within the family suggested an autosomal recessive 
inheritance, however no candidate disease genes were identified following bioinformatic 
analysis and filtering of the exome data. Given the previous findings, CDC45 and other 
autosomal recessive craniosynostosis disorder associated genes were manually re-examined; 
this identified a single paternally transmitted missense variant in CDC45, c.893C>T encoding 
p.Ala298Val. Visual analysis of the sequencing reads using Integrated Genomics Viewer29 
suggested lower coverage of exon 5 in both the two affected samples and the maternal sample 
compared with the paternal sequencing (Figure S1A). Analysis using MLPA probes 
confirmed a deletion encompassing only exon 5 of CDC45 in these three samples (Figure 
S1B). This would be predicted to delete a highly conserved portion of the protein, but 
translation would remain in-frame and therefore transcripts from this allele would not be 
predicted to undergo nonsense-mediated decay. This was confirmed by analysis of cDNA 
derived from maternal blood (Figure S1C). 
 
The human CDC45 mutational spectrum indicates partial loss of protein function 
CDC45 is an essential component in the preIC that establishes active replication at licensed 
origins (Figure 1). The majority of variants identified in CDC45 lead to amino acid 
substitutions (Figure 3A), which bioinformatic analysis predict to be damaging; we examined 
conservation of these residues as a measure of deleteriousness, and found all are conserved in 
vertebrates, with residues at several sites conserved through to yeasts (Figure 3B).   
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One conserved substitution, c.203A>G, p.Gln68Arg, occurred at the penultimate 
nucleotide in exon 3 suggesting that it might also impact on splicing in addition to any 
protein-level consequence (see next section). The three subjects (P4, P5, P8) with a 
truncating/null mutation (nonsense, frameshift deletion, or initiation codon mutation) on one 
allele all segregate an identical missense variant, c.1388C>T, p.Pro463Leu present on the 
trans allele; given the South Asian ancestry in all three subjects (ExAC South Asian allele 
frequency 0.000062), the presence of this variant is compatible with a founder effect. 
 
All individuals had at least one allele compatible with some residual function; none were 
biallelic for null mutations, consistent with the early embryonic lethality reported in a Cdc45 
knockout mouse (Cdc45 homozygotes die before E7.5, due to impaired proliferation of the 
inner cell mass13). Individuals who were compound heterozygotes for a loss-of-function and a 
substitution allele (p.Pro463Leu or p.Ala298Val) were particularly severely affected. 
 
Structural consequences of CDC45 mutations  
Missense mutations did not cluster within a specific domain of the protein (Figure 3A).  
However, a homology model derived from the recent high resolution cryo-electron 
microscopy study of the yeast CMG helicase complex30 demonstrated that a number of 
substituted residues are located within the core of the CDC45 protein (Figure 4A, B).  This 
core region corresponds to the known catalytic site of the bacterial RecJ orthologs of CDC45 
and its DHH phosphoesterase homologs.31, 32 Such substitutions would therefore be likely to 
perturb protein stability. In particular, the recurrent p.Pro463Leu substitution replaces a 
conserved proline residue with a likely essential role in N-capping of an alpha-helix (Figure 
4C).  Likewise, within the protein core the p.Asn76His substitution is expected to introduce a 
positive charge within, and thus disrupt, the predicted divalent cation coordination sphere 
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present in many members of the DHH phosphoesterase superfamily (Figure 4D).33, 34, 35 
Predictions of functional consequences for point mutations at other sites in the homology 
model were not possible, aside from the p.Pro321Thr substitution that is expected to disrupt 
the interaction of CDC45 with MCM2 (Figure 4E).  
 
Hypomorphic CDC45 Mutations act by Disrupting Transcript Splicing and Reducing 
Protein Levels 
Five of the alleles (in Family 1, 3, 9 and 10) were hypothesized to affect splicing (Table S4-, 
S5) and this was confirmed in the three samples available for extraction of RNA, in which we 
analyzed the effects of putative splicing mutations on cDNA.  
In two families (Family 1, 9), the only putative second disease variants present after 
filtering to remove common variants were synonymous, which generally are less likely to be 
pathogenic. These two variants (c.318C>T and c.333C>T) lie close together in exon 4 which 
is skipped for transcripts in which alternative splicing from exon 3 directly to exon 5 
generates a naturally occurring shorter isoform.36 This evolutionarily conserved instance of 
exon skipping is predicted to generate an in-frame protein product that lacks part of the 
highly conserved DHH phosphoesterase domain.32 RNA derived from these subjects (P1: 
c.318C>T, P9-1: c.333C>T) exhibited an increased ratio of exon 3/5 transcript to exon 3/4/5 
cDNA product compared to controls (Figure 5). In silico tools (Human Splice Finder and 
Sroogle)37, 38 predict the c.318C>T variant to disrupt exon splice enhancer sites, and the 
c.333C>T variant to enhance potential cryptic exonic splice silencer sites, both mechanisms 
by which these variants may promote the skipping of exon 4 (Table S5). The apparently 
nonsynonymous variant c.203A>G (mutation present in P9-1 and P9-2), which lies at the 
penultimate nucleotide of exon 3, was also shown to cause complete skipping of exon 3 in the 
cell line from P9-1 (Figure 5Bi). 
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We next sought to investigate the consequence of these mutations on the CDC45 
protein by assessing protein levels in cells from five subjects by immunoblotting for 
endogenous CDC45. In the three cell lines available from affected individuals 
(lymphoblastoid cell lines derived from P1, P2 and P9-1) and in primary amniocytes derived 
from P12-1 and P12-2, CDC45 levels were significantly lower than in multiple control cells 
or cell lines (P < 0.0001). Moreover, CDC45 levels were reduced below 50% in all cases, 
indicating a contribution from both alleles to reduced protein levels. This suggests that the 
missense mutations present in these cells or cell lines (P1, p.Asp226Gly; P2, p.Asn76His and 
p.Arg157Cys; P12, p.Ala298Val) each result in destabilization of CDC45 protein.   
Taken together with the nature of the mutations identified, the key demonstration of 
decreased cellular levels in several affected individuals confirm that variants identified were 
pathogenic and the mutations would most likely result in destabilization of CDC45 protein.  
 
Spectrum of Phenotypes associated with CDC45 Mutations and Correlation with 
Genotype  
In total we identified 15 subjects from 12 families with variants in CDC45 (Table 1, Figure 
2A). Individuals with biallelic CDC45 mutations exhibit substantial variation in severity, in 
part explained by ascertainment from two distinct cohorts of affected subjects 
(craniosynostosis for P1-P3, P12 and MGS for P4-P11). Nevertheless they manifest a 
recognizable phenotypic spectrum with overlapping clinical features (Table 2, Figure 2B-D). 
For example, although subjects P4-P11 all presented with the classical triad of MGS features 
(short stature from -1.3 to -7.7 SD, microtia and absent or hypoplastic patellae), 
craniosynostosis was also frequent, in contrast to MGS associated with mutations in preRC 
components. The severity of craniosynostosis varied widely from unilateral or bilateral 
coronal synostosis to multiple suture involvement (Figure 2C). The discordance for 
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craniosynostosis in two siblings with identical mutations (P9-1 and P9-2), indicates that this 
is not a fully penetrant phenotype. Conversely, individuals with a primary presentation of 
craniosynostosis also exhibited mild MGS features, such as hypoplastic ears (P1, P3, P12-1), 
mild short stature, and a similar facial gestalt including a small mouth (Figure 2B). The MGS 
feature of patellar hypoplasia was however not observed in any of the three individuals with 
craniosynostosis who presented postnatally (P1-P3). Thin eyebrows were present in subjects 
presenting with either craniosynostosis or MGS, a feature that has not been previously 
highlighted in these or related developmental disorders. Additionally anal abnormalities 
(imperforate anus or anterior placement) were present in seven subjects drawn from both 
cohorts. Growth failure and microcephaly were evident from birth in almost all subjects 
(Figure 2D), and both the microcephaly and height reduction were progressive throughout 
childhood. Carrier parents and heterozygous siblings were phenotypically normal, a point of 
particular note since CDC45 is located on 22q11.21, within the interval deleted in the 
22q11.2 deletion syndromes.39 
 
Discussion 
Here we identify multiple mutations in CDC45, implicating it is involved in the pathogenesis 
of both MGS and craniosynostosis. Previous work had established MGS as a disorder of 
replication licensing, with biallelic mutations in ORC1, ORC4, ORC6 and accessory proteins 
encoded by CDC6 and CDT1. Furthermore, a recent report has identified stabilizing 
mutations in GMNN, which likely act to inhibit CDT1 and consequently reduce licensing in 
G1.23 No mutations in any of the MCM subunits have been discovered in individuals with 
MGS, previously suggesting that MGS was limited to the upstream preRC components; 
indeed, a founder MCM4 mutation has been described causing a distinct entity - a genome 
instability syndrome of short stature, adrenal insufficiency and primary immunodeficiency.40, 
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41, 42 The identification of CDC45 is therefore surprising, given the well-established function 
of the CDC45 protein in replication activation and fork progression (Figure 1). Associating 
CDC45 mutations with MGS therefore expands understanding of the pathogenic basis of 
MGS, and given the number of individuals reported here, establishes CDC45 as a common 
cause of MGS syndrome, alongside ORC1 and CDT1. These mutations in individuals with 
MGS also raise the possibility that mutations in genes coding for other proteins involved in 
DNA replication may be implicated in MGS and/or craniosynostosis. 17, 43, 44, 45 
Following the initial identification of MGS mutations, several studies have proposed 
disease mechanisms distinct from the canonical role of the preRC in replication, such as 
dysregulated cilia formation or centrosome duplication.46, 47 Our identification of MGS 
mutations in distinct replication machinery, with similar growth and clinical characteristics 
seen in the preRC MGS individuals (including those with GMNN mutations), strongly favors 
a replication-based etiology for MGS. Notably, biallelic mutations in the helicase RECQL4 
(MIM 603780, also required for preIC formation and replication initiation44, 45), can cause a 
phenotype that overlaps with MGS; RAPADILINO syndrome (MIM 266280) is characterised 
by growth retardation and patellar agenesis, although diarrhoea, palatal anomalies and radial 
ray defects are also evident.45 Since CDC45 has been shown to bind several additional 
proteins in the preIC, for example TOPBP148 and MCM10,49 mutations of these other 
components may in future be implicated in MGS or disorders exhibiting overlapping features.  
A distinctive feature of MGS caused by CDC45 mutations is the frequent association 
with craniosynostosis. Only two previous MGS subjects have been reported with 
craniosynostosis, both with ORC1 mutations (P1 and P3 in Bicknell et al., 2011)19, therefore 
it is likely that the presence of craniosynostosis in MGS subjects is a strong predictor for 
CDC45 mutations. Craniosynostosis is also a feature of Baller-Gerold syndrome (MIM 
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218600), another RECQL4 disorder,45 further implicating replication initiation in the etiology 
of premature cranial suture closure.  
Disruption of the canonical function of CDC45 in replication initiation is consistent 
with the previously proposed models to explain the growth phenotype, which suggested that 
impaired replication in affected individuals disrupts cell division during periods of rapid 
proliferation in development, ultimately impairing organism growth and leading to a 
‘hypocellular’ dwarfism.20, 50 Partial loss of function mutations in CDC45, like those in 
preRC components, further indicate that strict regulation of replication is particularly required 
for the development of specific cartilaginous structures (ear, patella, trachea or bronchial 
tree),51 but the exact mechanism remains elusive and future studies with model organisms 
will be required. Similarly, the frequent occurrence of craniosynostosis in this cohort, along 
with the established premature suture fusion seen in subjects with RECQL4 mutations, 
highlights the importance of normal replication initiation and progression to maintain correct 
proliferation-differentiation balance in the cranial sutures.52  
In summary, we present genetic and functional evidence that mutations in CDC45 
cause Meier-Gorlin syndrome with craniosynostosis. The identification of these mutations in 
a DNA replication protein functioning downstream to the previously identified MGS genes 
reinforces the premise that the growth and cartilaginous phenotypes of MGS, as well as the 
premature cranial suture fusion seen here, are due to replication dysfunction. This 
identification also suggests new candidate genes in which mutations might underlie this 
disorder or component phenotypes. 
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Figure Legends 
Figure 1. Pre-Replication and Pre-Initiation Complexes in DNA Replication, Showing 
Components Mutated in MGS 
Previously identified MGS-associated genes (labelled with orange lettering) encode members 
of the pre-replication complex (preRC, upper cartoon); these components are involved in the 
licensing of replication origins during the G1 phase of the cell cycle. GMNN acts during 
other cell cycle phases to inhibit CDT1 but is degraded in late M (mitosis) phase (indicated 
by GMNN with dashed outline), permitting free CDT1 to participate in origin licensing in 
G1. In contrast, CDC45 contributes at the next major step in DNA replication, in which the 
coordinated action of many replication initiation factors including RECQL4 forms the pre-
initiation complex (PreIC, lower cartoon) to support the interaction of CDC45 and GINS1-4 
with the MCM helicase, converting the latent form to an active helicase and initiating the 
unwinding of DNA.  
 
Figure 2. Clinical Features of Individuals with Mutations in CDC45 
(A) Pedigrees of families segregating mutations in CDC45. Note consanguinity in Family 5, 
7 and 11 and that all parents and unaffected siblings available for testing were heterozygous 
for only one variant, consistent with autosomal recessive inheritance.  
(B) Facial appearance of individuals with CDC45 mutations. Many individuals demonstrate 
the facial characteristics of MGS including microtia, small mouth, full lips and micrognathia, 
but there is a marked spectrum of severity across the cohort. Note the consistent appearance 
of thin eyebrows.  
(C) CT head scans and plain skull radiographs of individuals with CDC45 mutations 
demonstrating premature fusion of cranial sutures. Note the discordance in suture fusion 
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between sibs P9-1 and P9-2. Imaging of P8 indicates progressive suture closure (P8 left 
panel, age 2 yr 4 m, P8 right panel, age 3 yr 8 m). Skull radiography of P5 demonstrates a 
copper-beaten appearance of the skull.  
(D) Individuals with CDC45 mutations have below average stature and many exhibited 
intrauterine growth retardation and microcephaly (both in utero and postnatal). SD, standard 
deviation; Lgt, length; OFC, occipitofrontal circumference; Wgt, weight; Hgt, height. Blue, 
individuals derived from craniosynostosis cohort; black, individuals derived from MGS 
cohort. 
 
Figure 3. Mutations in CDC45, and Conservation of Substituted Residues in 
Orthologous Proteins 
(A) Mutations identified in CDC45 include variants predicted or shown to affect splicing 
(blue, position in gene shown in upper panel), predicted missense substitutions (black), or 
truncating mutations (purple). Δex5 refers to the intragenic deletion encompassing exon 5 of 
CDC45 in family P12 (green). Mutations do not cluster within any specific domain of 
CDC45. Domain architecture of human CDC45 indicated as described in Yuan et al.26 The 
two alpha-beta domains are shown in purple and orange, respectively. The protruding helical 
motif (PHM) inserted in the first alpha-beta domain is shown in red. The middle all-helix 
interdomain (ID) is shown in blue, and the two linkers (L1 and L2) are shown in gray. 
 (B) Clustal Omega alignments of eukaryotic CDC45 proteins indicate mutated residues are 
well conserved, with several residues (such as p.Asn76, p.Arg157, p.Pro321 and p.Pro463) 
conserved as distantly as fungi. Blue shading indicates proportion of conserved amino acids. 
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Figure 4. Structural Consequences of CDC45 Substitutions  
(A) Structural model of human CDC45 demonstrating the spatial distribution of substitutions 
in the protein. Red boxes indicate position of missense mutations, with side-chains of these 
substituted residues displayed in green.  
(B) CDC45 in context of the S. cerevisiae CMG complex from the 3.8Å cryo-electron 
microscopy structure.26 
(C-E) Modeling of substitutions that cluster in the central core of CDC45. (C) Proline 463 is 
an evolutionarily conserved position, with an essential role in N-capping of the alpha-helix 
localized between Pro542 and Cys556 in yeast Cdc45 (Pro463 and Phe477 in human). Given 
the location of Pro463 in the CDC45 structural core, the substitution to leucine is predicted to 
have severe effects on the stability of this helix53 and therefore overall stability of the protein.  
(D) Asn76 is predicted to be part of the divalent cation coordination sphere. While the DHH 
domain of CDC45 is currently considered to be catalytically inert,30, 54 residues D26, D28, 
D99 and H101, corresponding to the catalytic core of prokaryotic RecJ exonucleases and the 
DHH superfamily of phosphoesterases, are conserved (highlighted by black boxes).26, 32, 55 
This suggests the continued presence of a divalent cation at this position (predicted divalent 
cation indicated by yellow sphere).  Asn76 is therefore thought to be part of a divalent cation 
coordination sphere which, in other homologs, is the phosphoesterase catalytic centre. The 
substitution to histidine would introduce a positive charge into the putative divalent cation 
coordination sphere, thereby disrupting the network of interactions among water molecules, 
charged residues and divalent cation/s observed in different members of the superfamily of 
DHH phosphoesterases.33, 34, 35 (E) Proline 321 (corresponding to Pro369 in yeast) is a key 
part of the CDC45 interacting surface with Mcm2,26 given that in yeast it lies within 3.5Å of 
Ile289 of Mcm2 (corresponding to Ile211 in human MCM2). Additionally, this proline has a 
key role in the N-capping of the alpha-helix localized between Leu370 and Gln374 in yeast 
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Cdc45.53 Therefore, substitution of proline 321 to threonine is likely not only to have effects 
on CDC45-MCM2 interaction but also on CDC45 protein stability. The interacting pair 
Pro321 (in CDC45) and Ile211 (corresponding to Ile289 in Mcm2) are shown in sticks 
(green) inside their van der Waals surfaces. 
 
Figure 5. Synonymous CDC45 Variants Alter Levels of Alternative Splicing of Exon 4 in 
Lymphoblastoid Cell Lines 
(A) The synonymous variant c.318C>T present in P1 increases the ratio of exon3/5 transcript 
compared to controls. (i) RT-PCR demonstrating an enrichment in the exon3/5 lower band. 
(ii) Results of qRT-PCR to assay the relative amounts of exon 4 in P1, P2 and four unaffected 
controls. Products were amplified with primers in exons 3 and 4, and compared with products 
generated from primers in exons 1 and 3. cDNA from P1 showed a 0.43-fold reduction in 
exons 3-4 relative to exons 1-3. Levels of exons 5-6 compared with exons 1-3 are also shown, 
no differences were observed. Error bars, standard deviation. n=3 experimental replicates of 
qPCR. (B) The synonymous variant c.333C>T together with the trans c.203A>G, 
p.Glu68Arg splice site variant identified in P9-1 and P9-2, increases aberrant splicing across 
this region of the gene. (i) RT-PCR demonstrating an increase in exon3/5 transcript and the 
creation of a novel transcript where exon 3 has been skipped due to the c.203A>G mutation. 
(ii) Total RNA extracted from LCLs derived from P9-1 was analyzed by qRT-PCR. Full 
length only transcripts were amplified using a forward primer (F 2/3) spanning the exon 2-
exon 3 boundary and a reverse primer (R 4/5) spanning the exon 4-exon 5 boundary. The 
transcript missing exon 4 was specifically amplified using the F 2/3 primer paired with a 
reverse primer (R 3/5) which spanned the exon 3-exon 5 boundary. Total amount of minus 
exon 4 (-Ex4) and full length (FL) transcript was normalized to GAPDH for P9-1 and control. 
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Error bars indicate standard deviation (n = 3 experiments).  A two tailed, unpaired student’s t-
test was performed and p-values are indicated. 
 
 
Figure 6. CDC45 Protein Levels are Significantly Reduced in Lymphoblastoid Cell 
Lines and Primary Amniocytes 
Cell lines from affected individuals (P1, P2, P9-1) and amniocytes derived from affected 
fetuses (P12-1 and P12-2) demonstrate a significant reduction in endogenous CDC45 levels 
compared to three independent controls (LCL samples - one way ANOVA comparing all 
LCL samples against C1, NS, p > 0.01, ****p < 0.0001, n = 5 biological replicates; 
amniocyte samples - one way ANOVA comparing all amniocyte samples against C4. ***p < 
0.001, ****p < 0.0001, n = 3 biological replicates).  
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Table 1. Mutations Identified in CDC45. 
Subject Country of Origin Allele 1 Allele 2 Segregation 
P1a UK c.318C>T, p.Val106= (SE) c.677A>G, p.Asp226Gly Het, M, P, (2)b 
P2 UK c.226A>C, p.Asn76His c.469C>T, p.Arg157Cys Het, M, P, (1) 
P3 USA c.653+5G>A (SE) c.1487C>T, p.Pro496Leu Het, M, P 
P4 Bangladesh c.1A>C, p.Met1? c.1388C>T, p.Pro463Leu nps 
P5 Bangladesh c.1270C>T, p.Arg424* c.1388C>T, p.Pro463Leu Het, M, P 
P6 Belgium c.791C>A, p.Ser264Tyr c.791C>A, p.Ser264Tyr Hom, M, P 
P7-1 Egypt c.1660C>T, p.Arg554Trp c.1660C>T, p.Arg554Trp Hom, M (P deceased) 
P7-2 Egypt c.1660C>T, p.Arg554Trp c.1660C>T, p.Arg554Trp Hom, M, P 
P8 Sri Lanka c.1388C>T, p.Pro463Leu c.1532delC, p.Pro511Glnfs*36 Het, M, P 
P9-1 Turkey c.203A>G, p.Gln68Arg (SE) c.333C>T, p.Asn111= (SE) Het, M, P 
P9-2 Turkey c.203A>G, p.Gln68Arg (SE) c.333C>T, p.Asn111= (SE) Het, M, P 
P10c New Zealand c.[464A>G; 961C>A], p.[Glu155Gly; Pro321Thr] c.1440+14C>T (SE) Het, M, P 
P11 Egypt c.1660C>T, p.Arg554Trp c.1660C>T, p.Arg554Trp Hom, M, P 
P12-1 Netherlands c.(485+1_486-1)_(630+1_631-1)del, p.Ile115_Glu162del c.893C>T, p.Ala298Val Het, M, P 
P12-2 Netherlands c.(485+1_486-1)_(630+1_631-1)del, p.Ile115_Glu162del c.893C>T, p.Ala298Val Het, M, P 
 
Refseq Accession: NM_003504.4 SE: splicing effect. Het, compound heterozygous in affected individual, nps, no parental samples available, M, mutation 
identified in mother, P, mutation identified in father, Hom, homozygous in affected individual. aMutation previously reported28 (note mutation numbering differs 
in previous publication due to different reference transcript). bNumbers in brackets indicate number of clinically unaffected siblings shown not to have inherited 
the compound heterozygous genotype. cSubject P10 segregates two rare missense variants on one allele, in combination with a splice region mutation on the 
second allele. Based on conservation of CDC45 residues across different species the p.Pro321Thr variant is more likely to be deleterious as this residue is 
conserved through to S. cerevisiae (Figure 3). 
 
 
 
28 
 
Table 2. Clinical Characteristics of Individuals with Mutations in CDC45. 
Subject Consan Gender 
Birth, SD Current Exam, SD MGS Features 
Thin 
Eyebrows 
Developmental 
Delay Craniosynostosis Other Clinical Features Gest. 
Lgt 
(cm) 
OFC 
(cm) 
Wgt 
(kg) Age 
Hgt 
(cm) 
OFC 
(cm) 
Wgt 
(kg) Microtia 
a/hypoplastic 
patella 
P1 N M 40 NA NA 
-0.7 
(3.2) 
28y 
-0.7 
(173) 
-0.4b 
(55.5) 
+1.3 
(85.7) 
+ - + none right unicoronal urethral stricture, mild 2/3/4 syndactyly of hands 
P2 N F 38 NA NA 
-1.2 
(2.5) 
4y 4m 
-0.9 
(100) 
-3.1 
(47.6) 
-0.8 
(15.3) 
- - + none bicoronal anterior anus, bilateral strabismus 
P3 N M 38 NA NA 
-1.7 
(2.4) 
16y 3m 
-3.6 
(147) 
-3.7 
(50.5) 
-3.9 
(35.3) 
+ - + mild bicoronal 
R choanal atresia, high 
palate, imperforate anus, 
vesicoureteral reflux, 
hypospadias, 2-3 syndactyly 
of toes, scoliosis, C1-C3 and 
C4-C7 fusion, bilateral radial 
head dislocation 
P4 N F 36 NA 
-2.9 
(28.5) 
-3.2 
(1.45) 
5y 5m 
-7.7 c 
(48) 
-8.3c 
(33) 
-6.1 
(9.9) 
+ + + severe large anterior fontanelle (x-ray) 
cleft palate, exorbitism, 
bilateral radial head 
dislocation, thoracic vertebral 
segmentation defects, digital 
clubbing, pulmonary 
hypoplasia, anterior anus, 
cliteromegaly 
P5 3rd F 40 NA NA 
-4.7 
(1.5) 
6y 
-4.6 
(93) 
-8.1 
(42.5) 
-7.5 
(9.2) 
+ + + none copper-beating on skull radiograph 
cleft palate, bowed legs, 
anorectal malformation 
P6 N M 34 
0.3 
(46.5) 
-1.1 
(30) 
-1.2 
(1.88) 
22y 
-4.8 
(145) 
-5.4 
(48) 
-8.4 
(32.5) 
+ + + severe bicoronal and bilambdoid  
AV block grade II, SN hearing 
loss, joint laxity, chiari I 
malformation, myopia 
P7-1 1st M term 
-4 
(43) 
-4 
(30) 
-2.5 
(2.4) 
3y 6m 
-4.1 
(83) 
-5.5 
(44) 
-6 
(8.5) 
+ + + none coronal, sagittal 
anal stenosis, budlike mouth, 
ASD, VSD, undescended 
testes, hypospadius 
P7-2 1st F term 
-4.9 
(41) 
-2.9 
(31) 
-2.2 
(2.45) 
5y 2m 
-3.5 
(94) 
-4 
(47) 
-4.2 
(11.5) 
+ + + none coronal, sagittal AV canal 
P8 N F 37 
-0.4 
(47) 
-4.6 
(27) 
-1.7 
(2.14) 
4y 
-4.9 
(82) 
-10.4 
(38.6) 
-7.6 
(7.5) 
+ 
lowset NA + NA 
bicoronal and 
bilambdoid, broad 
patent sagittal 
with bifid metopic 
suture  
vestibular, anterior anus, 
hearing mild conduction 
delay, proptosis, VSD, 
duodenal stenosis 
P9-1 N M 42 
-1.4 
(50) 
NA 
-1.5 
(3.2) 
7y 
-1.3 
(115) 
-2.3 
(50) 
-0.4 
(22) 
+ + + none none high arched palate, micropenis 
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P9-2 N M term 
0.5 
(52) 
-1.7 
(33) 
-1.2 
(3.0) 
16m 
-2.5 
(73) 
-4.7 
(43) 
-3.7 
(7.5) 
+ N/A + none 
bicoronal with 
widely patent 
metopic and 
sagittal sutures 
none 
P10 N F 36 NA 
-1.8 
(30) 
-1.5 
(2.04) 
25y 
-2.5 
(149) 
-4.7 
(49) 
NA + + + none bicoronal 
high palate, hearing loss, 
breast agenesis, heart block 
P11 1st F 40 NA NA 
-4.0 
(1.75) 
4y 7m 
-2.5 
(95) 
-4.6 
(-4.6) 
-3.2 
(12) 
+ + + none coronal and lambdoid small ASD 
P12-1 N F 22+3a 
-1.9 
(25) 
-3.9 
(15.5) 
-3.0 
(0.33) 
TOP + Not reported + N/A Yes anterior anus 
P12-2 N M 30+5 a 
-0.4 
(39.1) 
-2.9 
(24) 
-1.1 
(1.15) 
TOP lowset Not reported + N/A 
bicoronal, partial 
lambdoid, 
squamous and 
lateral parts of the 
occipital bone  
pre-axial polydactyly of both 
hands, small VSD, meconium 
peritonitis, multiple nodules of 
ectopic thymic tissue, high 
palate 
SD, standard deviation. Calculated using LMSgrowth56 and adjusted for sex and gestation, with the exception of a, where Z-scores were calculated using the Fenton 2013 
Growth Calculator.57 bmeasurement at 15 years of age, after surgery. cmeasurement at 5 months of age. NA, not available; TOP, termination of pregnancy. 
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Note on accession numbers for CDC45 
Human CDC45 encodes a 20-exon gene that has been annotated as including three major 
spliceforms. As well as the full-length version which encodes a protein of 598 amino acids, 
alternative splicing to skip either exon 7 alone or both exons 4 and 7 leads to shorter isoforms 
with in-frame deletions of 32 and 78 amino acids, respectively. Whereas exon 4 shows high 
conservation in mammalian species both in sequence and occurrence of exon skipping, 
neither is the case for exon 7, so the physiological significance of the isoform including exon 
7 is currently uncertain.  Virtually all previous publications investigating the structure and 
function of CDC45 employ the numbering of the middle-sized, 566 amino acid isoform, so 
for consistency with prior work all numbering used here refers to NM_003504.4. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure S1. Family 12 segregates a genomic deletion encompassing exon 5 of CDC45. 
 
(A) Manual interrogation of exome sequencing reads across the CDC45 gene suggested a decrease in coverage 
across exon 5 in both affected samples and the carrier mother, compared to the father, who carries the 
c.893C>T, p.Ala298Val variant. While the reduction in coverage was not statistically significant, the presence 
of a rare variant on the trans allele in both affected samples prompted further investigation. BAM files 
visualized using IGV. (B) MLPA, comparing the quantity of DNA in a test sample vs a synthetic control with 
multiple probes across CDC45, was performed in both affected samples and the mother, and all samples showed 
a deletion of exon 5. (Bi) Peak traces of control (red) and affected (blue). (Bii) Calculated ratio of DNA. Both 
probes for exon 5 demonstrate an approximately 50% reduction, consistent with a heterozygous deletion of exon 
5. Probes for exon 4 and exon 6 do not show a reduction, indicating the breakpoints for the deletion lie within 
intron 4 and intron 5, respectively. Reports generated using GeneMarker Software (SoftGenetics Inc.). (C) RT-
PCR and sequencing of cDNA from carrier parents in Family 12. (Ci) RT-PCR of exons 3-6 in CDC45 from 
cDNA derived from parents in Family 12. There is an increase in a lower migrating band in the mother, who 
carries the exon 5 deletion allele (a faint co-migrating lower band visible in all samples is caused by 
physiological skipping of exon 4, see figure 5). (Cii) Sequencing of each band from the maternal sample 
indicates the lower migrating band (labelled Band 2) comprises exons 3, 4 and 6, with complete skipping of 
exon 5, resulting in an in-frame transcript. 
 
 
 
 
 
 
Table S1. Experimental details for next-generation sequencing undertaken in this study. 
Family 
Clinical Diagnosis/ 
Study Focus Design Library Kit Platform 
Analysis Software 
Coverage Filtering parameters Control populations Mapping 
Variant 
Calling Annotation 
1 
Craniosynostosis 
(SC_2930), clinical 
genome sequencing 
Genome 
NEBNext DNA 
Sample Prep Master 
Mix Set 1 Kit 
Illumina 
HiSeq2000 
BWA1, Stampy 
(v1.0.12-1.0.22)2 
Platypus 
(v.0.2.4)3 ANNOVAR
4 28x Minor allele absent 1000 Genomes, ESP 
2 Craniosynostosis Exome TruSeq V2 Illumina HiSeq2000 
Novoalign 
(Novocraft 
Technologies) 
SAMtools 
(v0.1.19) ANNOVAR 55x Minor allele absent 1000 Genomes, ESP 
4 Primordial dwarfism Exome SureSelect V4 Illumina HiSeq2500 BWA, Stampy 
SAMtools, 
Dindel Ensembl VEP 50x 
MAF < 0.005, ≥ 1 
deleterious consequence 
prediction 
1000 Genomes, ESP 
12 Diagnostic Exome SureSelectXT V5 Illumina HiSeq2500 
Custom in-house pipeline MAGPIE 
(based on BAM-MEM and GATK) 70x SeattleSeq, LOVDplus 
GoNL, 1000 
Genomes 
MAF, minor allele frequency; GoNL, genomes of The Netherlands. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Primers and amplification conditions for resequencing. 
Dideoxy-sequencing primers to confirm variants in the craniosynostosis cohorta  
  
Variant Primers 
Primer sequence 5′→3 ′  
Product size (bp) Forward Reverse 
c.226A>C 
4F/4R TAGTGATGAAGGAAAAGGGGCCTCCTCG CTGTTCCCAGTCCCACAGGGTAGTCAG 314 c.318C>T 
c.469C>T 5F/5R ACCACGTATGGTGTAACTCTGGTGCCTCAC CTTGGCCTGGCAGGCTTCAGGATGAC 436 
c.653+5G>A 8F/8R CATGAGCCTTAGACTTCTCTGCTTCCTTAC ATCACACACATACCCAGAAAGGGGCTGCA 240 
c.677A>G 9F/9R GAGAGAGGCCACCTGACTGAGGCAAG CAGTCCTCACTTCTCAATAGGACCCTA 335 
c.1487C>T 16F/16R CATAGACAAAGAACCGGCGCTGCAAACTG GACACTAGAGGCAAATACCACTCTACTCAG 223 
  
Dideoxy-sequencing primers for CDC45 in the MGS cohortb  
Exon(s) Forward Reverse Product size (bp) 
1-2 GATTTGGCGGGAGTCTTG ACGCAGCACCCTCACCTC 382 
3 TCTTTTCAAGGTAAATTGCTAATGTC TGGAAATAGAATGCTGTGTCAAG 230 
4 AGTGATGAAGGAAAAGGGGC CCAAGAACACCAGGTGAGAC 274 
5 TCAGCTTATTAGGAAATGATAAGATTC CCACTGCCCTCAGTACACC 343 
6 CTGGGCCTACTGACTTCTGC TCACTTCAAGCTAGAATAACCTTTC 519 
7 TTTTCCAAAATATTTGGCTTCC AGGACACTGACCCCTGGAG 174 
8 TCAAGTCCAGTCTGGCTGC TTATGTGGCACTGACCAAGG 201 
9 CCTCATTGAGCCCAGGTG GTGGCTATGGTCAGGCTGTG 179 
10 CTGCCTGGTAAGAGCTGGAG ACCCACAGAGGGTGACAAAG 257 
11-12 CCACCTGCTGGAGTTACGAG CCCTTCACTTTAATGAACCTGG 610 
13 GCAGTGAGAGCTTGCCCAC CCCGTAACTGACCTCCCTG 293 
14-15 CAAGCAAACTATTTGTGACTTTGG GGAGCTCTCCAAGCACCTG 437 
16-17 CTCTGAGTGTTGAGCTGGGG AACTTGCTTGGTTCCAGGG 506 
18 TTCTGTGCCCTGTCTTGTG AGCAGGGCATCAGGGTC 199 
    
 Primers for Fluidigm resequencing in the craniosynostosis cohortc   
ID Forward Reverse Length (bp, 
excluding universal 
adaptors) 
CDC45_1 ACACTGACGACATGGTTCTACAAGTCTTGACCGCCGCC TACGGTAGCAGAGACTTGGTCTCCCCTCATCCCTTCCCCA 173 
CDC45_2 ACACTGACGACATGGTTCTACACCTCGGACGTGGATGCT TACGGTAGCAGAGACTTGGTCTCTCACTTGCTGTTCACCTCCT 186 
CDC45_3 ACACTGACGACATGGTTCTACAGTCCAGAGCCAGGTGACG TACGGTAGCAGAGACTTGGTCTCTGAAGGATCTTGCACGCAC 210 
CDC45_4 ACACTGACGACATGGTTCTACAAGATAGGCTTTGAAAACACTCTCTCT TACGGTAGCAGAGACTTGGTCTTGCTGTGTCAAGAAATTACAATTGAGTA 186 
CDC45_5 ACACTGACGACATGGTTCTACAATGAAGACACTATATTCTTTGTGTGTGAC TACGGTAGCAGAGACTTGGTCTTAGTCAGACACACACCTTACCAAG 167 
CDC45_6 ACACTGACGACATGGTTCTACATCAGAGGCTTAGTGATGAAGGAAAA TACGGTAGCAGAGACTTGGTCTATTGACGACATTGACTGGCCTAT 192 
CDC45_7 ACACTGACGACATGGTTCTACACCGTAGAAAGAGGAGAGGCTTAATT TACGGTAGCAGAGACTTGGTCTGATAGCTGTGAGAGACCCAAACT 215 
CDC45_8 ACACTGACGACATGGTTCTACAGGCCTACTGACTTCTGCCAAA TACGGTAGCAGAGACTTGGTCTGGCTTCTGGTGCTGGGAG 193 
CDC45_9 ACACTGACGACATGGTTCTACAGTGCCACCCATACCTCTGAC TACGGTAGCAGAGACTTGGTCTCCATGGTCTCTAATGGATGGCA 188 
CDC45_10 ACACTGACGACATGGTTCTACACTTCCTGTACTGCTACTTCCTGTT TACGGTAGCAGAGACTTGGTCTACATTTGAGGACACTGACCCC 164 
CDC45_11 ACACTGACGACATGGTTCTACAGCCTTAGACTTCTCTGCTTCCTT TACGGTAGCAGAGACTTGGTCTGTGGCACTGACCAAGGCA 145 
CDC45_12 ACACTGACGACATGGTTCTACACATCATCTCACTCCATCCCCC TACGGTAGCAGAGACTTGGTCTGCTATGGTCAGGCTGTGCA 200 
CDC45_13 ACACTGACGACATGGTTCTACATTCCCGCCACAACCACC TACGGTAGCAGAGACTTGGTCTCACCTGCTTTCCCTCCTGG 191 
CDC45_14 ACACTGACGACATGGTTCTACACTGCCTGGTAAGAGCTGGAG TACGGTAGCAGAGACTTGGTCTGAGTGTGTTCTCCTCATCCTCG 141 
CDC45_15 ACACTGACGACATGGTTCTACATTCAAGCTGTGGTCTGTGCA TACGGTAGCAGAGACTTGGTCTTTCTGGGATCTAGGGCAAGGA 194 
CDC45_16 ACACTGACGACATGGTTCTACAGCTTGCATGCTCCTTGACTG TACGGTAGCAGAGACTTGGTCTCTCCTGGAGCCGCTTCTG 144 
CDC45_17 ACACTGACGACATGGTTCTACAGTCGGTGTGTGGTGACCTC TACGGTAGCAGAGACTTGGTCTCTTTAATGAACCTGGATGTAATGAAGATAAATC 200 
CDC45_18 ACACTGACGACATGGTTCTACAGCTGTGTTTGCTCCCATGAC TACGGTAGCAGAGACTTGGTCTCAAACCCACAGCCCTCCT 207 
CDC45_19 ACACTGACGACATGGTTCTACAAACTCGCCAAGAAGCAGCT TACGGTAGCAGAGACTTGGTCTAGACGAAGCCACTGGTGC 161 
CDC45_20 ACACTGACGACATGGTTCTACATTACCAAGAGTTCCTGACAAGCA TACGGTAGCAGAGACTTGGTCTAATGGTCTGCTGGGTGGC 127 
CDC45_21 ACACTGACGACATGGTTCTACACAGTGGCTTCGTCTGACCAT TACGGTAGCAGAGACTTGGTCTGGCCAGCATCTAACTCCCC 201 
CDC45_22 ACACTGACGACATGGTTCTACACTCTGAGTGTTGAGCTGGGG TACGGTAGCAGAGACTTGGTCTGGACGAGTGGAAGCTGCTC 200 
CDC45_23 ACACTGACGACATGGTTCTACACATGTCTTGTGTGTCAGCAGC TACGGTAGCAGAGACTTGGTCTCCAGCCATGCCAACTTGC 187 
CDC45_24 ACACTGACGACATGGTTCTACAGTGAGCAGCTTCCACTCGT TACGGTAGCAGAGACTTGGTCTCTTCTCAAACGCCCTCCCAA 196 
CDC45_25 ACACTGACGACATGGTTCTACATCCCTTCTCACGGCTGTTTTT TACGGTAGCAGAGACTTGGTCTCCAAGTAGAAGCCTCCGTTGA 201 
 
MLPA Primer Sequencesd 
ID Sequence 
CDC45-EX4-5 GGGTTCCCTAAGGGTTGGAGGCCAGTCAATGTCGTCAATGTATA 
CDC45-EX4-3 CAACGATACCCAGGTACTTTTTGTGTCTAGATTGGATCTTGCTGGCAC 
CDC45-EX3-5 GGGTTCCCTAAGGGTTGGAGATAGGCTTTGAAAACACTCTCTCTCCAGGC 
CDC45-EX3-3 CTTGTTCCAGTGTGACCACGTGCAATATACGTCTAGATTGGATCTTGCTGGCAC 
CDC45-EX5B-5 GGGTTCCCTAAGGGTTGGAGCGCACACGGTTAGAAGAGGTGAGTTTGGGTCTCT 
CDC45-EX5B-3 CACAGCTATCCCAGAGGAACTTGCACTCCCAGAGGTCTAGATTGGATCTTGCTGGCAC 
CDC45-EX7-5 GGGTTCCCTAAGGGTTGGACTACGAGCAGTATGAATATCATGGGACATCGGTAAGTAT 
CDC45-EX7-3 GAATAGGTGGAACTCACTATAAAGTTCTGACTCCAGGGGTCTAGATTGGATCTTGCTGGCAC 
CDC45-EX5A-5 GGGTTCCCTAAGGGTTGGAGATGATGACCTTGAAGTTCCCGCCTATGAAGACATCTTCAG 
CDC45-EX5A-3 GGATGAAGAGGAGGATGAAGAGCATTCAGGAAATGACAGTGTCTAGATTGGATCTTGCTGGCAC 
CDC45-EX6-5 GGGTTCCCTAAGGGTTGGAGCTGTGGGGATAAATTCCTGGTGCATTTGCTCCACCTTTTGTT 
CDC45-EX6-3 CTCTTTGTCCCTGTATCAGGAGATAGTGGAGCAAACCATGCGGTCTAGATTGGATCTTGCTGGCAC 
aDNA was extracted from either venous blood collected into EDTA, lymphoblastoid cell lines or cultured fibroblasts established from skin biopsies obtained from the scalp 
incision at the time of surgical intervention. All DNA was extracted using the Nucleon Blood and Cell Culture (BACC) DNA extraction kit (Gen-Probe Inc.) according to the 
manufacturer’s instructions. PCR amplification of DNA was performed in a volume of 20 μl, containing 15 mM TrisHCl (pH 8.0), 50 mM KCl, 2.5 mM MgCl2, 100 μM each 
dNTP, 0.4 μM primers, and 0.75 units of FastStart Taq DNA Polymerase (Roche). Cycling conditions comprised a 5 min initial denaturation step at 94°C, followed by 35 
cycles of 94°C for 30 s, annealing at 63˚C for 30 s and extension at 72°C for 30 s, with a final extension at 72°C for 7 min. For dideoxy-sequencing, amplified PCR products 
were treated with ExoI (NEB) and shrimp alkaline phosphatase (FastAP; Thermo Scientific) to remove PCR primers and dNTPs respectively, by incubating at 37˚C for 30 
min, followed by 85˚C for 15 mins to denature the enzymes. Sequencing was then carried out using the BigDye Terminator v3.1 cycle sequencer system (Applied 
Biosystems). 
 
bPCR amplification of DNA was performed in a volume of 10 μl, using ReddyMix PCR master mix with 1.5 mM MgCl2 (Thermo Scientific), 0.5 μM primers and 10 ng 
DNA. Cycling conditions employed a touchdown approach and were as follows: 5 min initial denaturation step at 95°C , then 3 cycles of 94°C for 30 s, 65°C  for 30 s, 72°C 
for 45 s, then 3 cycles of 94°C for 30 s, 62°C for 30 s, 72°C for 45 s, then 3 cycles of 94°C for 30 s, 59°C for 30 s, 72°C for 45 s with a final 35 cycles of 94°C for 30 s, 56°C 
for 30 s, 72°C for 45 s, then a final extension of 72°C for 10 min. Dideoxy-sequencing was performed as in a. 
 
cPrimer pairs were designed to amplify 25 target regions of approximately 200 bp, covering all 19 exons and intron/exon boundaries for use with the Access ArrayTM  IFC 
system (Fluidigm). Universal CS1 and CS2 adaptor sequences were included on the 5′ ends of all target-specific forward and reverse primers, respectively. Primers were 
multiplexed into pools of 4-5 optimised pairs, with a final concentration of 1 µM per primer. Amplicon tagging, thermal cycling using the Biomark HDTM system (Fluidigm) 
and product harvesting were performed following the manufacturer’s instructions. Ion PGMTM sequence-specific adaptors and sample indexes were attached to each amplicon 
pool for DNA extracted from 48 individual craniosynostosis patients using a DNA Engine Dyad® Peltier thermal cycler (Bio-Rad). Indexed PCR products were pooled, 
purified with AMPure XP beads (Beckman Coulter Ltd.) and quantified using an Agilent High Sensitivity DNA Kit with the 2100 Bioanalyzer (Agilent Technologies, Inc) or 
the 2200 TapeStation (Agilent Technologies) with a High Sensitivity D1000 ScreenTape. In total, 467 patient samples were processed for downstream sequencing 
applications. Pooled and indexed PCR products were sequenced using the Ion PGMTM System (Life Technologies Ltd.). Pooled libraries were diluted to a final concentration 
of 10 pM and emulsion PCR and enrichment were performed with the Ion PGMTM Template OT2 200 Kit (Life Technologies Ltd.) according to the manufacturer’s 
instructions. Enriched target regions were sequenced with the Ion PGMTM Sequencing 200 Kit v2 for 125 cycles, using an Ion 318 chip.  
Underperforming amplicons (CDC45_2, CDC45_3 and CDC45_24) were re-sequenced independently. PCR products were amplified from 40 ng DNA with Q5® 
Hot Start High Fidelity polymerase (NEB) in the recommended standard reaction mixture, with the inclusion of Q5 High GC Enhancer. Cycling conditions were denaturation 
at 98°C for 30 s, followed by 35 cycles of 98°C for 10 s, 60°C for 30 s and 72°C for 30 s, followed by a final extension at 72°C for 2 min. Amplification products were 
diluted 100-fold and used in a second PCR reaction to incorporate Ion PGMTM sequence-specific adaptors and sample indexes as above, for 9 cycles. Pooled samples were 
purified and sequenced for 100 cycles as described above, using an Ion 314 chip. Sequence read alignment and variant analysis were performed using the Ion Torrent 
platform-specific software v4.2.1. In total 361 samples fulfilled minimum coverage parameters (x10 reads) for all amplicons. 
 
dThe MLPA reactions were performed according to a protocol based on the methods described previously.5, 6 Products were separated by capillary electrophoresis on the ABI 
3130 (Applied Biosystems) and data analyzed using GeneMarker (SoftGenetics Inc). Threshold ratios for deletion and duplication were set at <0.75 and >1.3, respectively. 
The colored primer sequences are universal for the MLPA procedure. 
Table S3. Primer sequences used for cDNA analysis of CDC45. 
Target Primers 
Primer sequence 5′→3′ 
Product size (bp) 
Forward Reverse 
Exon 1-3 TCCGATTTCCGCAAAGAGTTCTACG CAGCGTATATTGCACGTGGTCACA 138 
Exon 3-4 GGTGGCAAGAACTTGAAACTG ACATTGACGACATTGACTGGCCTAT 166 
Exon 3-5 GGTGGCAAGAACTTGAAACTG ATGTCTTCATAGGCGGGAAC 238/100 if exon 4 skipped 
Exon 5-6 GTTCCCGCCTATGAAGACAT CTCCTCCGCATGGTTTGCTC 137 
Exon 2F-5R GACGTGGATGCTCTGTGTGC GCTTCTCAGAAGGCTCTGACC 
394/301 if exon 3 skipped /256 
if exon 4 skipped 
Exon 2_3F-5_4R AGATCCTTCAGGCCTTGTTCC TAATTTGATCTGGGTATCGTTGTATAC 251 
Exon 2_3F-5_3R AGATCCTTCAGGCCTTGTTCC TAATTTGATCTGTTCTTTATGCTCAAG 113 
GAPDH GGACTCCACGACGTACTCAGCGCCAGC GTGGATATTGTTGCCATCAATGACC 213 
 
  
Table S4. In silico prediction of mutation effects on canonical splice sites. 
Patient(s) Mutation Allele Sequence MAXENT Score 
Sum 
Difference 
Sum 
Variation 
Significance 
Threshold Significant
a 
P3 c.653+5G>A 
G (WT) tcagtaagg 8.61 
5.95 -69% -30% Yes – 5´ donor site lost A (MUT) tcagtaaag 2.66 
P9-1 & 
P9-2 
c.203A>G, 
p.Gln68Arg 
A (WT) caggtattg 8.35 
3.48 -42% -30% Yes – 5´ donor site lost G (MUT) cgggtattg 4.87 
P10 c.1440+14C>T 
C (WT) caggcgggt 0.81 
-7.75 +1157% +30% Yes – cryptic 5´ donor site created T (MUT) caggtgggt 8.56 
aSignificance based on thresholds applied by prediction software, Alamut Batch (Interactive Biosciences Inc) and Human Splicing Finder.7 
 
Table S5. In silico splicing predictions for synonymous mutations in CDC45.  
Patient(s) Mutation Motif affected Predicted Consequence 
P1 c.318C>T, p. V106V Multiple potential silencing motifs created Exonic splice enhancer motif lost Skipping of exon 4 
P9-1 & P9-2 c.333C>T, p.N111N SRp40 exonic splice enhancer motif lost Skipping of exon 4 
Predictions calculated using Human Splicing Finder.7 
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